Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants

Lindsey N. Micel, John J. Tentler, Aik-Choon Tan, Heather M. Selby, Kelsey L. Brunkow, Kelli M. Robertson, S. Lindsey Davis, Peter J. Klauck, Todd M. Pitts, Esha Gangolli, Robyn Fabrey, Shawn M. O'Connell, Patrick W. Vincent, S. Gail Eckhardt

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The goal of this study was to investigate the activity of the selective MEK1/2 inhibitor TAK-733 in both melanoma cell lines and patient-derived melanoma xenograft models. In vitro cell proliferation assays using the sulforhodamine B assay were conducted to determine TAK-733 potency and melanoma responsiveness. In vivo murine modeling with eleven patientderived melanoma explants evaluated daily dosing of TAK-733 at 25 or 10 mg/kg. Immunoblotting was performed to evaluate ontarget activity and downstream inhibition by TAK-733 in both in vitro and in vivo studies. TAK-733 demonstrated broad activity in most melanoma cell lines with relative resistance observed at IC 50 > 0.1 mmol/L in vitro. TAK-733 also exhibited activity in 10 out of 11 patient-derived explants with tumor growth inhibition ranging from 0% to 100% ( P < 0.001-0.03). Interestingly, BRAFV600E and NRAS mutational status did not correlate with responsiveness to TAK-733. Pharmacodynamically, pERK was suppressed in sensitive cell lines and tumor explants, confirming TAK-733-mediated inhibition of MEK1/2, although the demonstration of similar effects in the relatively resistant cell lines and tumor explants suggests that escape pathways are contributing to melanoma survival and proliferation. These data demonstrate that TAK-733 exhibits robust tumor growth inhibition and regression against human melanoma cell lines and patient-derived xenograft models, suggesting that further clinical development in melanoma is of scienti fic interest. Particularly interesting is the activity in BRAF wild-type models, where current approved therapy such as vemurafenib has been reported not to be active.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalMolecular Cancer Therapeutics
Volume14
Issue number2
DOIs
Publication statusPublished - 2015 Feb 1
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Melanoma
Cell Line
Neoplasms
Tumor Cell Line
lissamine rhodamine B
Heterografts
TAK 733
Growth
Immunoblotting
Cell Proliferation
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Micel, L. N., Tentler, J. J., Tan, A-C., Selby, H. M., Brunkow, K. L., Robertson, K. M., ... Eckhardt, S. G. (2015). Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Molecular Cancer Therapeutics, 14(2), 317-325. https://doi.org/10.1158/1535-7163.MCT-13-1012

Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. / Micel, Lindsey N.; Tentler, John J.; Tan, Aik-Choon; Selby, Heather M.; Brunkow, Kelsey L.; Robertson, Kelli M.; Davis, S. Lindsey; Klauck, Peter J.; Pitts, Todd M.; Gangolli, Esha; Fabrey, Robyn; O'Connell, Shawn M.; Vincent, Patrick W.; Eckhardt, S. Gail.

In: Molecular Cancer Therapeutics, Vol. 14, No. 2, 01.02.2015, p. 317-325.

Research output: Contribution to journalArticle

Micel, LN, Tentler, JJ, Tan, A-C, Selby, HM, Brunkow, KL, Robertson, KM, Davis, SL, Klauck, PJ, Pitts, TM, Gangolli, E, Fabrey, R, O'Connell, SM, Vincent, PW & Eckhardt, SG 2015, 'Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants', Molecular Cancer Therapeutics, vol. 14, no. 2, pp. 317-325. https://doi.org/10.1158/1535-7163.MCT-13-1012
Micel, Lindsey N. ; Tentler, John J. ; Tan, Aik-Choon ; Selby, Heather M. ; Brunkow, Kelsey L. ; Robertson, Kelli M. ; Davis, S. Lindsey ; Klauck, Peter J. ; Pitts, Todd M. ; Gangolli, Esha ; Fabrey, Robyn ; O'Connell, Shawn M. ; Vincent, Patrick W. ; Eckhardt, S. Gail. / Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 2. pp. 317-325.
@article{1aba931d6877401094773f62b42e129f,
title = "Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants",
abstract = "The goal of this study was to investigate the activity of the selective MEK1/2 inhibitor TAK-733 in both melanoma cell lines and patient-derived melanoma xenograft models. In vitro cell proliferation assays using the sulforhodamine B assay were conducted to determine TAK-733 potency and melanoma responsiveness. In vivo murine modeling with eleven patientderived melanoma explants evaluated daily dosing of TAK-733 at 25 or 10 mg/kg. Immunoblotting was performed to evaluate ontarget activity and downstream inhibition by TAK-733 in both in vitro and in vivo studies. TAK-733 demonstrated broad activity in most melanoma cell lines with relative resistance observed at IC 50 > 0.1 mmol/L in vitro. TAK-733 also exhibited activity in 10 out of 11 patient-derived explants with tumor growth inhibition ranging from 0{\%} to 100{\%} ( P < 0.001-0.03). Interestingly, BRAFV600E and NRAS mutational status did not correlate with responsiveness to TAK-733. Pharmacodynamically, pERK was suppressed in sensitive cell lines and tumor explants, confirming TAK-733-mediated inhibition of MEK1/2, although the demonstration of similar effects in the relatively resistant cell lines and tumor explants suggests that escape pathways are contributing to melanoma survival and proliferation. These data demonstrate that TAK-733 exhibits robust tumor growth inhibition and regression against human melanoma cell lines and patient-derived xenograft models, suggesting that further clinical development in melanoma is of scienti fic interest. Particularly interesting is the activity in BRAF wild-type models, where current approved therapy such as vemurafenib has been reported not to be active.",
author = "Micel, {Lindsey N.} and Tentler, {John J.} and Aik-Choon Tan and Selby, {Heather M.} and Brunkow, {Kelsey L.} and Robertson, {Kelli M.} and Davis, {S. Lindsey} and Klauck, {Peter J.} and Pitts, {Todd M.} and Esha Gangolli and Robyn Fabrey and O'Connell, {Shawn M.} and Vincent, {Patrick W.} and Eckhardt, {S. Gail}",
year = "2015",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-13-1012",
language = "English",
volume = "14",
pages = "317--325",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants

AU - Micel, Lindsey N.

AU - Tentler, John J.

AU - Tan, Aik-Choon

AU - Selby, Heather M.

AU - Brunkow, Kelsey L.

AU - Robertson, Kelli M.

AU - Davis, S. Lindsey

AU - Klauck, Peter J.

AU - Pitts, Todd M.

AU - Gangolli, Esha

AU - Fabrey, Robyn

AU - O'Connell, Shawn M.

AU - Vincent, Patrick W.

AU - Eckhardt, S. Gail

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The goal of this study was to investigate the activity of the selective MEK1/2 inhibitor TAK-733 in both melanoma cell lines and patient-derived melanoma xenograft models. In vitro cell proliferation assays using the sulforhodamine B assay were conducted to determine TAK-733 potency and melanoma responsiveness. In vivo murine modeling with eleven patientderived melanoma explants evaluated daily dosing of TAK-733 at 25 or 10 mg/kg. Immunoblotting was performed to evaluate ontarget activity and downstream inhibition by TAK-733 in both in vitro and in vivo studies. TAK-733 demonstrated broad activity in most melanoma cell lines with relative resistance observed at IC 50 > 0.1 mmol/L in vitro. TAK-733 also exhibited activity in 10 out of 11 patient-derived explants with tumor growth inhibition ranging from 0% to 100% ( P < 0.001-0.03). Interestingly, BRAFV600E and NRAS mutational status did not correlate with responsiveness to TAK-733. Pharmacodynamically, pERK was suppressed in sensitive cell lines and tumor explants, confirming TAK-733-mediated inhibition of MEK1/2, although the demonstration of similar effects in the relatively resistant cell lines and tumor explants suggests that escape pathways are contributing to melanoma survival and proliferation. These data demonstrate that TAK-733 exhibits robust tumor growth inhibition and regression against human melanoma cell lines and patient-derived xenograft models, suggesting that further clinical development in melanoma is of scienti fic interest. Particularly interesting is the activity in BRAF wild-type models, where current approved therapy such as vemurafenib has been reported not to be active.

AB - The goal of this study was to investigate the activity of the selective MEK1/2 inhibitor TAK-733 in both melanoma cell lines and patient-derived melanoma xenograft models. In vitro cell proliferation assays using the sulforhodamine B assay were conducted to determine TAK-733 potency and melanoma responsiveness. In vivo murine modeling with eleven patientderived melanoma explants evaluated daily dosing of TAK-733 at 25 or 10 mg/kg. Immunoblotting was performed to evaluate ontarget activity and downstream inhibition by TAK-733 in both in vitro and in vivo studies. TAK-733 demonstrated broad activity in most melanoma cell lines with relative resistance observed at IC 50 > 0.1 mmol/L in vitro. TAK-733 also exhibited activity in 10 out of 11 patient-derived explants with tumor growth inhibition ranging from 0% to 100% ( P < 0.001-0.03). Interestingly, BRAFV600E and NRAS mutational status did not correlate with responsiveness to TAK-733. Pharmacodynamically, pERK was suppressed in sensitive cell lines and tumor explants, confirming TAK-733-mediated inhibition of MEK1/2, although the demonstration of similar effects in the relatively resistant cell lines and tumor explants suggests that escape pathways are contributing to melanoma survival and proliferation. These data demonstrate that TAK-733 exhibits robust tumor growth inhibition and regression against human melanoma cell lines and patient-derived xenograft models, suggesting that further clinical development in melanoma is of scienti fic interest. Particularly interesting is the activity in BRAF wild-type models, where current approved therapy such as vemurafenib has been reported not to be active.

UR - http://www.scopus.com/inward/record.url?scp=84923367858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923367858&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-1012

DO - 10.1158/1535-7163.MCT-13-1012

M3 - Article

VL - 14

SP - 317

EP - 325

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -